Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a company announcement posted on the Hong Kong Stock Exchange with no indication of financial results, management changes, dividends, or other specific categories. It is a voluntary announcement about product development (clinical trial approval) rather than a financial report, capital update, or governance filing. Therefore, it falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-15 English
UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY
M&A Activity Classification · 1% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding a connected transaction to dispose of 30.0704% equity interest in a target company, confirming shareholder approval and next steps. It is not a financial results release, director dealing, dividend notice, or AGM material. Instead, it relates to a corporate disposal transaction (sale of equity interest), which falls under M&A activity. Therefore, the appropriate classification is M&A Activity (TAR).
2026-04-08 English
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME OF THE COMPANY
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the grant of restricted shares to selected participants under its 2018 Share Award Scheme. It does not contain full financial statements (so not an Annual or Interim Report), it is not a proxy or AGM information, nor is it an earnings release or governance or legal proceedings notice. It is also not reporting a director’s personal share transaction, a dividend, a major shareholding change, or a delisting. It describes share awards (share‐based compensation) using existing shares held by a trustee, rather than new share issuance or a buyback by the company. No other specific category applies, so it falls under the general regulatory announcement fallback category.
2026-04-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026
Regulatory Filings Classification · 1% confidence The document is a FF301 form titled “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities.” It is a routine compliance return filed with HKEX disclosing monthly movements in issued shares, share options, public float sufficiency, and related share capital information. It is not an annual or interim financial report, not an earnings release, not a proxy statement, and not a share issue announcement per se, but rather a regulatory filing for ongoing disclosure under the listing rules. Therefore, the most appropriate classification is the fallback category “Regulatory Filings” (RNS).
2026-04-01 English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2+ BREAST CANCER MEETS PRIMARY ENDPOINT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement on the Hong Kong Exchange detailing Phase III clinical trial results for a drug combination. It is not financial reporting (no earnings, NAV, interim/annual report), not management or board changes, not a financing or M&A transaction, nor an ESG or governance report. It is a general regulatory announcement that does not fit any more specific category, making it the fallback category “Regulatory Filings.”
2026-03-31 English
VOLUNTARY ANNOUNCEMENT - ADOPTION OF THE 2026 SHARE AWARD SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is a voluntary announcement by a Hong Kong listed company regarding the adoption of a new 2026 Share Award Scheme under Chapter 17 of the HK Listing Rules. It details the scheme’s purposes, limits, administration, vesting conditions and compliance measures. This is not a full financial report or earnings release, nor is it a transcript or management change notice. It announces a new share‐based incentive plan (a capital change mechanism), fitting the Share Issue/Capital Change category.
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.